You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tyrosine kinase inhibitors

Showing 1 - 25 of 7,917
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia Trial in Poitiers (treatment of TKI in CML)

Not yet recruiting
  • Tyrosine Kinase Inhibitors
  • Chronic Myeloid Leukemia
  • treatment of TKI in CML
  • Poitiers, France
    Chu Poitiers
Feb 21, 2023

B-cell Malignancies Undergoing Treatment With Bruton Tyrosine

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +4 more
  • Non-Interventional Study
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Nov 22, 2023

Non Small Cell Lung Cancer Trial in Mexico City (Metformin Hydrochloride, Placebo)

Recruiting
  • Non Small Cell Lung Cancer
  • Metformin Hydrochloride
  • Placebo
  • Mexico City, Mexico
    Instituto Nacional de Cancerologia
Jul 21, 2022

r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase

Not yet recruiting
  • B-cell Lymphoma
  • Beijing, Beijing, China
    Deparment of Hematology, Peking University People's Hospital
Aug 9, 2022

Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes

Active, not recruiting
  • Patients Diagnosed as Chronic Meyloid Leukemia
  • Tyrosine kinase Inhibitors (Imatinib & Nilotinib)
  • Assiut, Egypt
    Assiut University Hospital
Feb 19, 2022

Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor Trial in Rotterdam

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
    • Rotterdam, Netherlands
      Erasmus MC
    Feb 2, 2022

    CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

    Recruiting
    • CML
    • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
    • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
      FUNDALEU
    Jun 29, 2023

    Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase, Tyrosine Kinase Inhibitors Trial in Shenzhen (olverembatinib)

    Recruiting
    • Olverembatinib
    • +2 more
    • Shenzhen, Guangdong, China
      Shenzhen Second People's Hospital
    Jul 26, 2022

    Myeloproliferative Tumor, Chronic Phase Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia Trial in San Francisco (Online

    Recruiting
    • Myeloproliferative Neoplasm
    • +2 more
    • Online Mindfulness Meditation
    • Internet-Based Webinars
    • San Francisco, California
      University of California San Francisco
    Aug 9, 2022

    Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial (BGB-11417)

    Not yet recruiting
    • Leukemia
    • +4 more
    • (no location specified)
    Jul 27, 2022

    Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest Trial in New Hyde Park (Medtronic

    Recruiting
    • Atrial Fibrillation
    • +4 more
    • Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
    • New Hyde Park, New York
      Northwell (Northshore University/Long Island Jewish Hospitals)
    Dec 1, 2022

    Tyrosine Kinase Inhibitors in Trastuzumab Emtansine Resistant

    Recruiting
    • Breast Cancer
    • Nanjing, Jiangsu, China
      Jiangsu Provincial People's Hospital
    Feb 7, 2022

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023

    Carcinoma, Adenoid Cystic Trial in Qingdao (EGFR-TK Inhibitor)

    Recruiting
    • Carcinoma, Adenoid Cystic
    • EGFR-TK Inhibitor
    • Qingdao, Shandong, China
      Qingdao central Hospital
    Nov 1, 2021

    NSCLC With EGFR Mutation Trial in Mexico City (Glutamine plus L. reuteri)

    Recruiting
    • Non-Small Cell Lung Cancer With EGFR Mutation
    • Glutamine plus L. reuteri
    • Mexico City, Mexico
      Instituto Nacional de Cancerologia de Mexico
    May 2, 2023

    NSCLC Stage IIIB~IV Trial in Taipei (Atezolizumab Injection; bevacizumab Injection)

    Recruiting
    • NSCLC Stage IIIB~IV
    • Atezolizumab Injection; bevacizumab Injection
    • Taipei, Taiwan
      National Taiwan University Hospital
    Jan 18, 2022

    Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and

    Completed
    • Leukemia
    • No Intervention
    • Cambridge, Massachusetts
      Takeda
    Feb 28, 2023

    METAstatic Gastrointestinal Stromal Tumors (METAGIST)

    Recruiting
    • Gastro Intestinal Stromal Tumor
    • oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR as per recommendations
    • Bordeaux, France
      Institut Bergonié, Comprehensive Cancer Center
    Dec 1, 2022

    TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy

    Recruiting
    • Chronic Myeloid Leukemia
    • Pisa, Italy
    • +1 more
    Jan 4, 2022

    ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

    Completed
    Has Results
    • ALK-positive NSCLC
    • Sollentuna, Sweden
      Pfizer Innovations AB
    Mar 14, 2022

    Called ROCURS, to Learn About COVID-19 Related Outcomes in

    Active, not recruiting
    • Malignant Solid Tumors
    • +2 more
    • Whippany, New Jersey
      Bayer
    Feb 2, 2023

    ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Pure

    Completed
    • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Sep 23, 2021

    Adult Chronic Lymphocytic Leukemia Receiving Oral Venetoclax

    Recruiting
    • Chronic Lymphocytic Leukemia
      • London, London, City Of, United Kingdom
      • +9 more
      Jan 13, 2023

      Leukemia, Chronic Myelogenous Trial in China (asciminib, best available treatment)

      Recruiting
      • Leukemia, Chronic Myelogenous
      • Chongqing City, Chongqing, China
      • +23 more
      Jan 18, 2023

      Non Small Cell Lung Cancer, CNS Progression Trial in Aurora (Temozolomide plus Osimertinib, Temozolomide plus Lorlatinib)

      Active, not recruiting
      • Non Small Cell Lung Cancer
      • CNS Progression
      • Temozolomide plus Osimertinib
      • Temozolomide plus Lorlatinib
      • Aurora, Colorado
        University of Colorado Hospital
      May 12, 2022